Home › Compare › MNBEY vs ABBV
MNBEY yields 1.44% · ABBV yields 3.06%● Live data
📍 MNBEY pulled ahead of the other in Year 5
Combined, MNBEY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MNBEY + ABBV for your $10,000?
MinebeaMitsumi Inc. manufactures and supplies machined components, and electronic devices and components in Japan, Europe, the United States, Asia, and internationally. It operates through four segments: Machined Components, Electronic Devices and Components, MITSUMI Business, and U-Shin business segment. The company offers bearing products, including miniature and small-sized ball bearings, rod end and spherical bearings, roller bearings, bushings, precision machined parts for aircraft, and medium- and large-sized ball bearings for aerospace use. It also provides bearing-related products, such as pivot assemblies and precision mechanical assemblies; and fasteners, defense related special components, and electromagnetic clutches and brakes. In addition, the company offers rotary components comprising fan motors, blowers, hybrid type stepping motors, PM stepping motors, small diameter/high speed PM stepping motors, brush DC motors, small brushless motors, power brushless motors, polygon mirror scanner motors, HDD spindle motors, high-pressure blowers, rotation angle sensors, fan units, and FDB motors. Further, it provides lighting devices for LCDs; resonant devices; and measuring components comprising strain gauges, force sensors, load cells, pressure gauges, torque transducers, vector sensors, digital indicators, and tensile and compression testing machines; sensors and sensor related products; coils, switches, and connectors; frequency and optical devices, power supply components, industrial machinery components, home security products, automotive components, and semiconductors. It offers its products for use in PCs and peripheral equipment, information and telecommunications equipment, household electrical appliances, automobiles, and aircraft parts. The company was formerly known as Minebea Co., Ltd. and changed its name to MinebeaMitsumi Inc. in January 2017. MinebeaMitsumi Inc. was incorporated in 1951 and is headquartered in Tokyo, Japan.
Full MNBEY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.